The BPC-157 papers worth opening

Begin with the interruption, then the subjects

I'd begin with the VEGFR2 experiment that blocked the reported vessel-growth effect, then put it beside the rat-and-dog pharmacokinetic work. Mechanism and clearance are different questions; reading them together makes the word stable less slippery.

The rat gastric-ulcer paper and diclofenac-toxicity model give cytoprotection its specific experimental setting. The NSAID-counteraction review gathers the rodent findings rather than adding a human treatment test.

Give the human papers separate space

The two-adult intravenous safety pilot, interstitial-cystitis pilot and knee-pain case series are short human windows onto different questions. The 2025 musculoskeletal review places them in the much larger preclinical literature and notes the replication problem.

For safety mechanisms, the rat serotonin-synthesis paper, rat serotonin-syndrome study and cultured tendon-cell growth-hormone receptor work deserve attention without promotion into documented human harms.

FDA ingredient rules and advisory records

The 503A bulk-substance framework, withdrawn nominations with retained safety concerns, July 2026 advisory agenda and interim compounding guidance belong together. An agenda, a nomination and an ingredient rule are different kinds of record. An advisory document will never earn a final-decision role from me.